ORPHA:543
Burkitt lymphoma
Also known as: Small non-cleaved cell lymphoma
Publications
33,441
Trials
223
Interventional, condition-specific
Researchers
1,234
Distinct authors in sample
Gene link
MYC
No Known Disease Relationship
Readiness
3/6
Stages with a signal
Clinical definition (Orphanet)
Burkitt lymphoma is a rare form of malignant mature B-cell non-Hodgkin lymphoma.
How rare: How common this is has not been clearly measured.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0007243
- MeSH:D002051
- OMIM:113970
- UMLS:C0006413
- NCIT:C2912
Additional Mondo synonyms (7)
Burkitt lymphoma/leukemia · Burkitt's lymphoma · Burkitt's tumour · Burkitt's tumour or lymphoma · burkitt lymphoma, somatic · small non-cleaved cell lymphoma · small non-cleaved cell lymphoma, Burkitt's type
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
3/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedPartial
No Known Disease Relationship — MYC
- LiteraturePresent
33,441 matched papers (11,394 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialPresent
223 matched on ClinicalTrials.gov (24 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
33,441
33,441 papers — among the better-studied rare conditions, though still a fraction of common-disease literature (breast cancer: over 700,000). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
33,441 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
11,394 in the last 10 years · low confidence
Phrase hits: 33,441 · MeSH hits: 0
Who's working on it?
1,234
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Liu Y6 papers · 2026
Department of Hematology Oncology Chongqing University Cancer Hospital Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment Chongqing China.
Papers in Europe PMC - 02
- 03Zhang Y6 papers · 2025
Medical Oncology Department, Pediatric Oncology Center, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing Key Laboratory of Pediatric Hematology Oncology, Key Laboratory of Major Disease in Children, Ministry of Education, Beijing, 100045, China.
Papers in Europe PMC - 04Chen Y5 papers · 2025
Dazhou Vocational and Technical College, Dazhou, Sichuan, China.
Papers in Europe PMC - 05Moormann AM5 papers · 2026
Division of Immunology and Infectious Diseases, Department of Medicine, University of Massachusetts Chan Medical School, Worcester, MA, USA. ann.moormann@umassmed.edu.
Papers in Europe PMC - 06Bailey JA4 papers · 2026
Department of Pathology & Laboratory Medicine, Brown University, Providence, RI, USA.
Papers in Europe PMC - 07Jiang J4 papers · 2026
Department of Radiology, the Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Yunnan Cancer Centre, Kunming, China.
Papers in Europe PMC - 08Li J4 papers · 2026
Department of Hematology Oncology Chongqing University Cancer Hospital Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment Chongqing China.
Papers in Europe PMC - 09Wang X4 papers · 2026
Department of Gynecology, Beijing University First Hospital Ningxia Women's and Children's Hospital, Ningxia, China.
Papers in Europe PMC - 10Yan J4 papers · 2024
Department of Hematology, Liaoning Medical Center for Hematopoietic Stem Cell Transplantation, the Second Hospital of Dalian Medical University, Dalian 116027, China; Liaoning Key Laboratory of Hematopoietic Stem Cell Transplantation and Translational Medicine, Blood Stem Cell Transplantation Institute, Dalian Key Laboratory of hematology, Diamond Bay Institute of Hematology, the Second Hospital of Dalian Medical University, Dalian 116027, China; Department of Pediatric, Pediatric Oncology and Hematology Center, the Second Hospital of Dalian Medical University, Dalian 116027, China. Electronic address: yanjsdmu@dmu.edu.cn.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
223
interventional trials for this specific condition
223 interventional trials matched this specific condition name; 24 currently recruiting in our sample.
Data as of 27 July 2026
223 interventional trials — more than 73% of diseases in the trials denominator have none at all (5114 of 7003; this disease is at the 99.4th percentile).
low confidence · 99.4th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
223 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT06395103·RECRUITING·Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
Conditions: B-cell Acute Lymphoblastic Leukemia · Diffuse Large B-cell Lymphoma · Burkitt Lymphoma · Neuroblastoma·Matched via name phrase
- NCT07724457·NOT YET RECRUITING·Testing the Addition of a New Anti-Cancer Drug, Glofitamab to Usual Chemotherapy for Burkitt and Double Hit Lymphoma
Conditions: Recurrent Burkitt Lymphoma · Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements · Refractory Burkitt Lymphoma · Refractory High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements·Matched via name phrase
- NCT03314974·RECRUITING·Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
Conditions: Acute Leukemia · Acute Myeloid Leukemia · Acute Lymphoblastic Leukemia · Lymphoma·Matched via name phrase
- NCT03223610·RECRUITING·Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
Conditions: Lymphoma · Non-Hodgkin Lymphoma · Diffuse Large B-Cell Lymphoma · Burkitt Lymphoma·Matched via name phrase
- NCT07662928·NOT YET RECRUITING·Epcoritamab in Combination With Dose Adjusted EPOCH-R for High-risk Burkitt Lymphoma (BL), The BEDROCK Study
Conditions: Adult Burkitt Lymphoma·Matched via name phrase
- NCT02393157·RECRUITING·Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL
Conditions: Non-Hodgkin Lymphoma · Burkitt Lymphoma · Diffuse Large B-Cell Lymphoma · Primary Mediastinal B-cell Lymphoma·Matched via name phrase
- NCT05544019·RECRUITING·Study of SGR-1505 in Mature B-Cell Neoplasms
Conditions: Mature B-Cell Neoplasm · Non Hodgkin Lymphoma · DLBCL · Waldenstrom Macroglobulinemia·Matched via name phrase
- NCT01371630·RECRUITING·Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia
Conditions: B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 · B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative · Burkitt-Like Lymphoma With 11q Aberration · High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements·Matched via name phrase
- NCT07097363·RECRUITING·Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma
Conditions: B-Cell Non-Hodgkin Lymphoma · Burkitt Lymphoma · Diffuse Large B-Cell Lymphoma, Not Otherwise Specified · EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified·Matched via name phrase
- NCT05990465·RECRUITING·LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies
Conditions: Non Hodgkin Lymphoma · Diffuse Large B Cell Lymphoma · Follicular Lymphoma · Marginal Zone Lymphoma·Matched via name phrase
- NCT04195633·RECRUITING·Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
Conditions: Acute Leukemia · Acute Lymphoblastic Leukemia · Acute Myeloid Leukemia · Adult Diffuse Large Cell Lymphoma·Matched via name phrase
- NCT03136146·RECRUITING·Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
Conditions: Recurrent Acute Lymphoblastic Leukemia · Recurrent Adult Lymphoblastic Lymphoma · Recurrent Burkitt Leukemia · Recurrent Burkitt Lymphoma·Matched via name phrase
- NCT07168291·NOT YET RECRUITING·Novel Bispecific AbTCR (Anti-CD19/CD22)-T Cells in Relapsed or Refractory B-cell Lymphoma
Conditions: Diffuse Large B Cell Lymphoma (DLBCL) · Follicular Lymphoma ( FL) · Burkitt Lymphoma·Matched via name phrase
- NCT05518383·RECRUITING·B-cell Mature Non-Hodgkin's Lymphoma Treatment Protocol in Children and Adolescents 2021
Conditions: Non-hodgkin Lymphoma,B Cell · Burkitt Lymphoma · Primary Mediastinal Lymphoma · Primary CNS Lymphoma·Matched via name phrase
- NCT05389423·RECRUITING·Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas
Conditions: Diffuse Large Cell Lymphoma · Non-Hodgkin Lymphoma · Burkitt Lymphoma · Plasmablastic Lymphoma·Matched via name phrase
Observational and natural-history studies
16 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
Recruiting or not-yet-recruiting
- NCT03375619·RECRUITING·Long-term Follow-up Study of Patients Receiving CAR-T Cells
Conditions: Chronic Lymphocytic Leukemia · Lymphomas Non-Hodgkin's B-Cell · Lymphoma, Small Lymphocytic · Mantle Cell Lymphoma·Matched via name phrase
- NCT06796517·RECRUITING·Immunotherapy in Lymphoma
Conditions: Relapsed/refractory High Grade B Cell Lymphoma · High Grade B-cell Lymphoma · Diffuse Large B Cell Lymphoma Relapsed · Primary Mediastinal Large B-Cell Lymphoma·Matched via name phrase
- NCT06899581·RECRUITING·Gut Health in Children With Cancer
Conditions: AML (Acute Myelogenous Leukemia · HLH · Burkitt Lymphoma/Leukemia·Matched via name phrase
- NCT04425421·RECRUITING·Recommendations for the Treatment of Children With Burkitt's Lymphoma
Conditions: Burkitt Lymphoma·Matched via name phrase
- NCT06131801·RECRUITING·Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Conditions: Hematologic Malignancy · Leukemia · Lymphoma · Acute Lymphocytic Leukemia·Matched via name phrase
- NCT03869619·RECRUITING·REal World Data in LYmphoma and Survival in Adults
Conditions: Diffuse Large B Lymphoma (DLBCL) · Follicular Lymphoma (FL) · Mantle Cell Lymphoma (MCL) · Marginal Zone Lymphoma (MZL)·Matched via name phrase
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Burkitt lymphoma" OR "Small non-cleaved cell lymphoma" OR "Burkitt lymphoma/leukemia" OR "Burkitt's lymphoma" OR "Burkitt's tumour" OR "Burkitt's tumour or lymphoma" OR "burkitt lymphoma, somatic" OR "small non-cleaved cell lymphoma, Burkitt's type"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Burkitt lymphoma" OR "Small non-cleaved cell lymphoma" OR "Burkitt lymphoma/leukemia" OR "Burkitt's lymphoma" OR "Burkitt's tumour" OR "Burkitt's tumour or lymphoma" OR "burkitt lymphoma, somatic" OR "small non-cleaved cell lymphoma, Burkitt's type"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 223 interventional · 16 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
- Publication count (33441) is extremely high with unknown/missing prevalence — treat as possible over-matching, not proven research intensity
Ingested 2026-07-26T14:16:05.946Z
